HemoBioTech to Present at the EQUITIES 57th Anniversary Spring Conference

DALLAS--(BUSINESS WIRE)--HemoBioTech (OTCBB: HMBT, www.hemobiotech.com), a biopharmaceutical company focused on developing and commercializing the first viable human blood substitute, will present at the EQUITIES 57^th Anniversary Spring Conference to be held at the Princeton Club on April 18^th, in New York City.

HemoBioTech CEO Arthur Bollon, PhD, will provide an overview of the company and an update on its lead product, HemoTech, potentially the first viable human blood substitute. Dr. Bollon will also address the unique properties of HemoTech and strategies for its commercialization.

The EQUITIES conference is an all-day event featuring special presentations from emerging public company CEOs from a wide range of sectors. The conference provides an opportunity for promising emerging growth companies to connect with the investment community.

About HemoBioTech, Inc.

HemoBioTech, a Dallas-based biopharmaceutical company, is engaged in the development of HemoTech, a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. HemoTech is composed of bovine hemoglobin that is chemically modified with ATP, adenosine, and GSH. HemoTech not only can carry oxygen in the blood, but can also induce erythropoiesis (red blood cell production). The company believes that HemoTech, due to its novel structure, may possess properties that diminish the intrinsic toxicities which have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S. by prior holders of this technology. HemoTech is being subjected to further studies and testing to confirm and possibly expand on these results. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other conditions. For further information, please visit our website at http://www.hemobiotech.com.

Safe Harbor Statement

Except for historical information, the matters discussed in this news release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief, or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech’s Annual Report on Form 10-KSB for the year ended December 31, 2006, as amended, and HemoBioTech’s other reports filed with the Securities and Exchange Commission.